BioMarin Announces Appointment of Timothy P. Walbert to Board of Directors

Core Viewpoint - BioMarin Pharmaceutical Inc. has appointed Timothy P. Walbert, former chairman, president, and CEO of Horizon Therapeutics, to its Board of Directors effective February 24, 2025 [1][2]. Group 1: Appointment Details - Timothy P. Walbert has over 30 years of experience in the pharmaceutical industry, having held leadership roles at various companies including IDM Pharma, NeoPharm Inc., and Abbott [2]. - Walbert led Horizon Therapeutics from its founding in 2008 until its acquisition by Amgen in 2023 and is currently a senior advisor at Amgen [2]. Group 2: Company Statements - Alexander Hardy, CEO of BioMarin, expressed enthusiasm about Walbert's appointment, highlighting his operational expertise and patient-centered approach [3]. - Walbert stated his commitment to BioMarin's strategy focused on innovation, growth, and value creation, emphasizing the importance of prioritizing patient needs [3]. Group 3: Company Overview - BioMarin is a global biotechnology company based in San Rafael, California, founded in 1997, with a focus on developing medicines for rare genetic conditions [4]. - The company has a strong track record of innovation, with eight commercial therapies and a robust clinical and preclinical pipeline [4].